UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 35

Sortiert nach

Tu1878 FILGOTINIB DECREASES MOLECULAR MARKERS OF JAK1 SIGNAL TRANSDUCTION IN CROHN'S DISEASE: CONCORDANCE WITH ENDOSCOPY AND HISTOPATHOLOGY

Gastroenterology (New York, N.Y. 1943), 2020-05, Vol.158 (6), p.S-1200-S-1201

2020

Link zum Volltext

Verfügbarkeit prüfen

Mirikizumab as Induction and Maintenance Therapy for Ulcerative Colitis

The New England journal of medicine, 2023-06, Vol.388 (26), p.2444-2455

2023

Link zum Volltext

Verfügbarkeit prüfen

Su1779 SUBCUTANEOUS INFLIXIMAB (CT-P13 SC) FOR ULCERATIVE COLITIS: 2-YEAR EXTENSION RESULTS OF THE LIBERTY-UC STUDY

Gastroenterology (New York, N.Y. 1943), 2024-05, Vol.166 (5), p.S-810-S-810

2024

Link zum Volltext

Verfügbarkeit prüfen

1028 SUBCUTANEOUS INFLIXIMAB (CT-P13) AS MAINTENANCE THERAPY FOR CROHN'S DISEASE: A PHASE 3, RANDOMIZED, PLACEBO-CONTROLLED STUDY (LIBERTY-CD)

Gastroenterology (New York, N.Y. 1943), 2023-05, Vol.164 (6), p.S-221-S-221

2023

Link zum Volltext

Verfügbarkeit prüfen

Tu1747 INTERIM RESULTS FROM THE RANDOMIZED VERDICT TRIAL TO DETERMINE THE OPTIMAL TREATMENT TARGET IN PATIENTS WITH ULCERATIVE COLITIS

Gastroenterology (New York, N.Y. 1943), 2023-05, Vol.164 (6), p.S-1107-S-1108

2023

Link zum Volltext

Verfügbarkeit prüfen

Tu1701 SUBCUTANEOUS INFLIXIMAB (CT-P13 SC) AS MAINTENANCE THERAPY FOR ULCERATIVE COLIITS: A PHASE 3, RANDOMIZED, PLACEBO-CONTROLLED STUDY: RESULTS OF THE LIBERTY-UC STUDY

Gastroenterology (New York, N.Y. 1943), 2023-05, Vol.164 (6), p.S-1083-S-1084

2023

Link zum Volltext

Verfügbarkeit prüfen

S907 Guselkumab Improves Abdominal Pain and Bowel Urgency Symptoms in Patients With Moderately to Severely Active Ulcerative Colitis: Results From the Phase 3 QUASAR Induction Study

The American journal of gastroenterology, 2023-10, Vol.118 (10S), p.S677-S677

2023

Link zum Volltext

Verfügbarkeit prüfen

Guselkumab in Patients With Moderately to Severely Active Ulcerative Colitis: QUASAR Phase 2b Induction Study

Gastroenterology (New York, N.Y. 1943), 2023-12, Vol.165 (6), p.1443-1457

2023

Link zum Volltext

Verfügbarkeit prüfen

Tu1863 TRANSCRIPTIONAL AND MICROBIAL BIOMARKERS OF RESPONSE TO ANTI-TL1A THERAPY IN ULCERATIVE COLITIS: THE PHASE 2A TUSCANY STUDY

Gastroenterology (New York, N.Y. 1943), 2020-05, Vol.158 (6), p.S-1193-S-1193

2020

Link zum Volltext

Verfügbarkeit prüfen

Tu1738 – Biomarker and Pharmacokinetic Data from the Turandot Ii Open-Label Extension Study of the Anti-Mucosal Addressin Cell Adhesion Molecule-1 (MADCAM-1) Antibody Shp647 in Patients with Ulcerative Colitis

Gastroenterology (New York, N.Y. 1943), 2019-05, Vol.156 (6), p.S-1105-S-1106

2019

Link zum Volltext

Verfügbarkeit prüfen

Tu1728 – Long-Term Efficacy and Pharmacodynamics of the Anti-Mucosal Addressin Cell Adhesion Molecule-1 (Madcam-1) Monoclonal Antibody Shp647 in Crohn's Disease: the Opera Ii Study

Gastroenterology (New York, N.Y. 1943), 2019-05, Vol.156 (6), p.S-1101-S-1101

2019

Link zum Volltext

Verfügbarkeit prüfen

Tu1737 – Efficacy of the Anti-Mucosal Addressin Cell Adhesion Molecule-1 (MADCAM-1) Antibody Shp647 in Ulcerative Colitis: Results from the Open-Label Extension Study Turandot Ii

Gastroenterology (New York, N.Y. 1943), 2019-05, Vol.156 (6), p.S-1105-S-1105

2019

Link zum Volltext

Verfügbarkeit prüfen

P036 LONG-TERM SAFETY AND EFFICACY OF THE ANTI-MUCOSAL ADDRESSIN CELL ADHESION MOLECULE-1 (MADCAM-1) ANTIBODY SHP647 IN ULCERATIVE COLITIS: AN OPEN-LABEL EXTENSION STUDY (TURANDOT II)

Gastroenterology (New York, N.Y. 1943), 2019-02, Vol.156 (3), p.S25-S26

2019

Link zum Volltext

Verfügbarkeit prüfen

P037 LONG-TERM SAFETY, EFFICACY AND PHARMACOKINETICS OF THE ANTI-MUCOSAL ADDRESSIN CELL ADHESION MOLECULE-1 (MADCAM-1) MONOCLONAL ANTIBODY SHP647 IN CROHN’S DISEASE: THE OPERA II STUDY

Gastroenterology (New York, N.Y. 1943), 2019-02, Vol.156 (3), p.S26-S27

2019

Link zum Volltext

Verfügbarkeit prüfen

1027 SAFETY, TOLERABILITY, AND EFFICACY OF ANTI-TL1A ANTIBODY PF-06480605 IN TREATMENT OF ULCERATIVE COLITIS: THE OPEN-LABEL, MULTICENTER, PHASE 2A TUSCANY STUDY

Gastroenterology (New York, N.Y. 1943), 2020-05, Vol.158 (6), p.S-206-S-207

2020

Link zum Volltext

Verfügbarkeit prüfen

Differences in esophageal corpus motility in patients with pathological and non-pathological gastroesophageal reflux

Medical science monitor, 2006-09, Vol.12 (9), p.CR387-CR392

2006

Link zum Volltext

Verfügbarkeit prüfen

Sa1746 - Long-Term Safety and Efficacy of the Anti-Madcam Monoclonal Antibody Shp647 for the Treatment of Crohn's Disease: The Opera II Study

Gastroenterology (New York, N.Y. 1943), 2018-05, Vol.154 (6), p.S-378-S-379

2018

Link zum Volltext

Verfügbarkeit prüfen

Su1930 - Maintenance of Clinical Effect in Patients with Moderate-to-Severe Crohn’s Disease Treated with Filgotinib, a Selective jak1 Inhibitor: Exploratory 20-Week Data Analysis of the Phase 2 Fitzroy Study

Gastroenterology (New York, N.Y. 1943), 2017-04, Vol.152 (5), p.S601-S601

2017

Link zum Volltext

Verfügbarkeit prüfen

Su1920 - Efficacy of Filgotinib, a Selective jak1 Inhibitor, is Independent of Prior Anti-TNF Exposure: Subgroup Analysis of the Phase 2 Fitzroy Study in Moderate-To-Severe Crohn’s Disease

Gastroenterology (New York, N.Y. 1943), 2017-04, Vol.152 (5), p.S597-S597

2017

Link zum Volltext

Verfügbarkeit prüfen

Maintenance of Clinical Effect in Patients with Moderate-to-Severe Crohn’s Disease Treated with Filgotinib, a Selective jak1 Inhibitor: Exploratory 20-Week Data Analysis of the Phase 2 Fitzroy Study

Gastroenterology (New York, N.Y. 1943), 2017-04, Vol.152 (5), p.S601

2017

Link zum Volltext

Verfügbarkeit prüfen

Long-Term Safety, Efficacy and Pharmacokinetics of the Anti-Mucosal Addressin Cell Adhesion Molecule-1 (MAdCAM-1) Monoclonal Antibody SHP647 in Crohnʼs Disease: The OPERA II Study: 606

The American journal of gastroenterology, 2018-10, Vol.113 (Supplement), p.S347-S348

2018

Link zum Volltext

Verfügbarkeit prüfen

Long-Term Safety of the Anti-Mucosal Addressin Cell Adhesion Molecule-1 (MAdCAM-1) Antibody SHP647 in Ulcerative Colitis: An Open-Label Extension Study (TURANDOT II): 605

The American journal of gastroenterology, 2018-10, Vol.113 (Supplement), p.S347-S347

2018

Link zum Volltext

Verfügbarkeit prüfen

Maintenance of Clinical Effect in Patients with Moderateto-Severe Crohn’s Disease Treated with Filgotinib, a Selective jak1 Inhibitor: Exploratory 20-Week Data Analysis of the Phase 2 Fitzroy Study

Gastroenterology (New York, N.Y. 1943), 2017, Vol.152 (5), p.S601-S601

2017

Link zum Volltext

Verfügbarkeit prüfen

812c Filgotinib (GLPG0634), an Oral JAK1 Selective Inhibitor, Induces Clinical Remission in Patients With Moderate-to-Severe Crohn's Disease: Results From the Phase 2 FITZROY Study Interim Analysis

Gastroenterology (New York, N.Y. 1943), 2016-04, Vol.150 (4), p.S1267-S1267

2016

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 35

Suche als RSS-Feed

Aktive Filter

KollektionEBSCO_Psychology & Behavioral Sciences Collection

KollektionNUS Single-Journal Subscriptions

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(30)
Mit Volltextzugriff
(26)

Publikationsform

Artikel
(35)

Sprache

Englisch
(35)
Japanisch
(1)

Erscheinungsjahr

n.n

Zeitschrift / Serie

Neu hinzugefügt

... seit 30 Tagen
(3)

Menü

Weitere Dienste

Einstellungen

Tu1878 FILGOTINIB DECREASES MOLECULAR MARKERS OF JAK1 SIGNAL TRANSDUCTION IN CROHN'S DISEASE: CONCORDANCE WITH ENDOSCOPY AND HISTOPATHOLOGY

Mirikizumab as Induction and Maintenance Therapy for Ulcerative Colitis

Su1779 SUBCUTANEOUS INFLIXIMAB (CT-P13 SC) FOR ULCERATIVE COLITIS: 2-YEAR EXTENSION RESULTS OF THE LIBERTY-UC STUDY

905 DISEASE CLEARANCE AFTER 16 WEEKS OF TREATMENT WITH VEDOLIZUMAB IN PATIENTS WITH MODERATE TO SEVERE ULCERATIVE COLITIS: AN INTERIM ANALYSIS FROM THE VERDICT TRIAL

1028 SUBCUTANEOUS INFLIXIMAB (CT-P13) AS MAINTENANCE THERAPY FOR CROHN'S DISEASE: A PHASE 3, RANDOMIZED, PLACEBO-CONTROLLED STUDY (LIBERTY-CD)

Tu1747 INTERIM RESULTS FROM THE RANDOMIZED VERDICT TRIAL TO DETERMINE THE OPTIMAL TREATMENT TARGET IN PATIENTS WITH ULCERATIVE COLITIS

Tu1701 SUBCUTANEOUS INFLIXIMAB (CT-P13 SC) AS MAINTENANCE THERAPY FOR ULCERATIVE COLIITS: A PHASE 3, RANDOMIZED, PLACEBO-CONTROLLED STUDY: RESULTS OF THE LIBERTY-UC STUDY

S907 Guselkumab Improves Abdominal Pain and Bowel Urgency Symptoms in Patients With Moderately to Severely Active Ulcerative Colitis: Results From the Phase 3 QUASAR Induction Study

Guselkumab in Patients With Moderately to Severely Active Ulcerative Colitis: QUASAR Phase 2b Induction Study

Tu1863 TRANSCRIPTIONAL AND MICROBIAL BIOMARKERS OF RESPONSE TO ANTI-TL1A THERAPY IN ULCERATIVE COLITIS: THE PHASE 2A TUSCANY STUDY

Tu1738 – Biomarker and Pharmacokinetic Data from the Turandot Ii Open-Label Extension Study of the Anti-Mucosal Addressin Cell Adhesion Molecule-1 (MADCAM-1) Antibody Shp647 in Patients with Ulcerative Colitis

Tu1728 – Long-Term Efficacy and Pharmacodynamics of the Anti-Mucosal Addressin Cell Adhesion Molecule-1 (Madcam-1) Monoclonal Antibody Shp647 in Crohn's Disease: the Opera Ii Study

Tu1737 – Efficacy of the Anti-Mucosal Addressin Cell Adhesion Molecule-1 (MADCAM-1) Antibody Shp647 in Ulcerative Colitis: Results from the Open-Label Extension Study Turandot Ii

P036 LONG-TERM SAFETY AND EFFICACY OF THE ANTI-MUCOSAL ADDRESSIN CELL ADHESION MOLECULE-1 (MADCAM-1) ANTIBODY SHP647 IN ULCERATIVE COLITIS: AN OPEN-LABEL EXTENSION STUDY (TURANDOT II)

P037 LONG-TERM SAFETY, EFFICACY AND PHARMACOKINETICS OF THE ANTI-MUCOSAL ADDRESSIN CELL ADHESION MOLECULE-1 (MADCAM-1) MONOCLONAL ANTIBODY SHP647 IN CROHN’S DISEASE: THE OPERA II STUDY

1027 SAFETY, TOLERABILITY, AND EFFICACY OF ANTI-TL1A ANTIBODY PF-06480605 IN TREATMENT OF ULCERATIVE COLITIS: THE OPEN-LABEL, MULTICENTER, PHASE 2A TUSCANY STUDY

Differences in esophageal corpus motility in patients with pathological and non-pathological gastroesophageal reflux

Sa1746 - Long-Term Safety and Efficacy of the Anti-Madcam Monoclonal Antibody Shp647 for the Treatment of Crohn's Disease: The Opera II Study

Su1930 - Maintenance of Clinical Effect in Patients with Moderate-to-Severe Crohn’s Disease Treated with Filgotinib, a Selective jak1 Inhibitor: Exploratory 20-Week Data Analysis of the Phase 2 Fitzroy Study

Su1920 - Efficacy of Filgotinib, a Selective jak1 Inhibitor, is Independent of Prior Anti-TNF Exposure: Subgroup Analysis of the Phase 2 Fitzroy Study in Moderate-To-Severe Crohn’s Disease

Maintenance of Clinical Effect in Patients with Moderate-to-Severe Crohn’s Disease Treated with Filgotinib, a Selective jak1 Inhibitor: Exploratory 20-Week Data Analysis of the Phase 2 Fitzroy Study

Long-Term Safety, Efficacy and Pharmacokinetics of the Anti-Mucosal Addressin Cell Adhesion Molecule-1 (MAdCAM-1) Monoclonal Antibody SHP647 in Crohnʼs Disease: The OPERA II Study: 606

Long-Term Safety of the Anti-Mucosal Addressin Cell Adhesion Molecule-1 (MAdCAM-1) Antibody SHP647 in Ulcerative Colitis: An Open-Label Extension Study (TURANDOT II): 605

Maintenance of Clinical Effect in Patients with Moderateto-Severe Crohn’s Disease Treated with Filgotinib, a Selective jak1 Inhibitor: Exploratory 20-Week Data Analysis of the Phase 2 Fitzroy Study

812c Filgotinib (GLPG0634), an Oral JAK1 Selective Inhibitor, Induces Clinical Remission in Patients With Moderate-to-Severe Crohn's Disease: Results From the Phase 2 FITZROY Study Interim Analysis

Aktive Filter

Suchergebnisse filtern